Bendalis
Private Company
Funding information not available
Overview
Bendalis GmbH is a private, commercial-stage pharmaceutical company specializing in generic oncology and supportive care products. Founded in 2006 and headquartered in Oberhaching (near Munich), it operates with a therapeutics business model, generating revenue through the distribution of a portfolio of established injectable and oral generic drugs. The company leverages a close partnership with its sister company, Lyomark Pharma GmbH, a contract manufacturer, and focuses on the German and select international markets through a network of distribution partnerships.
Technology Platform
Integrated generic drug development, manufacturing (via sister company Lyomark), and distribution platform focused on sterile injectable and niche oncology therapeutics. Relies on GMP/GDP-certified quality systems and regulatory expertise rather than a novel discovery platform.
Opportunities
Risk Factors
Competitive Landscape
Bendalis competes with large global generic pharmaceutical companies (e.g., Teva, Sandoz, Viatris) as well as European specialty generics players. Its differentiation lies in its focused expertise in sterile injectable oncology drugs, vertical integration with Lyomark, and a partnership-driven commercial model for niche and supportive care products, allowing it to compete effectively in specialized segments.